8 results about "Potassium oxonate" patented technology

The invention provides a method for constructing an animal chronic gouty arthritis model, which comprises the following steps: a hyperuricemia model establishment stage: feeding a tested animal with a special feed containing oteracil potassium and yeast; establishing a chronic gouty arthritis model: repeatedly injecting urate into the tested animal; meanwhile, oteracil potassium is used for intragastric administration of the tested animal. On the basis of feeding with oteracil potassium combined with a special yeast feed, oteracil potassium solution is injected, blood uric acid level fluctuation is induced on the basis of blood uric acid increase, and urate crystals are injected repeatedly, so that the disease cause and pathological process of chronic gouty arthritis are simulated to the greatest extent; a chronic gouty arthritis animal model is successfully established by injecting urate crystals into joints of experimental animals repeatedly for a long time, inducing repeated attack of local acute inflammation of the joints and simulating pathological characteristics of chronic gouty arthritis.

The present application relates to the technical field of hyperuricemia modeling, and particularly relates to a method for inducing and constructing a cynomolgus monkey hyperuricemia model and application thereof, comprising the following steps: S1: selecting male cynomolgus monkeys as model animals; S2: administering an inducing agent to the experimental animals, wherein the inducing agent is composed of hydrochlorothiazide, potassium oxonate and adenine. The inducing agent is added to ordinary monkey feed for normal feeding of the experimental animals, the intake dose of hydrochlorothiazide is 0.1 g / kg / day, the intake dose of potassium oxonate is 0.2 g / kg / day, the intake dose of adenine is 0.1 g / kg / day, and 10% fructose water is used to replace ordinary drinking water at the same time. The present application can induce a stable hyperuricemia state in the cynomolgus monkey body by means of dietary induction, combined use of hydrochlorothiazide, potassium oxonate and adenine, compared with a traditional model induced by a single intraperitoneal injection of a drug, the present application better simulates the pathogenic cause of human hyperuricemia, and is easier to operate.

The application discloses a hyperuricemia non-human primate model and a construction method thereof, and belongs to the technical field of experimental animals. The construction method comprises the following steps: using a non-human primate, i.e., a cynomolgus monkey, as a model animal, orally administering potassium oxonate and intravenously injecting myo-inositol, so that the blood uric acid content of the cynomolgus monkey is significantly increased within 0.5-8 hours, and the process can be inhibited by a uric acid-lowering drug allopurinol, and based on this, a hyperuricemia model of a non-human primate can be formed. Compared with a model constructed by using rodents, the hyperuricemia non-human primate model constructed by the application can better simulate the related symptoms and physiological processes of human hyperuricemia, and provides a preclinical effect evaluation tool for the research and development of nutrients and drugs in related fields.

The invention belongs to the technical field of animal model construction, and particularly relates to a hyperuricemia modeling method based on combination of yeast feed and medicine, which comprises the following steps: feeding feed is prepared by mixing the following raw materials in percentage by mass: 30-35% of yeast, 0.1-5% of uric acid inducer and the balance of rat basal feed. Wherein the uric acid inducer is at least one of glucose, ethylenediamine tetraacetic acid, beta-mercaptoethanol and cysteine; rats are selected and fed with feeding feed, the rats freely eat and drink water, and the rats are fed for at least 6 days; during feeding, a mixture of oteracil potassium and hypoxanthine is fed every day. The hyperuricemia rat model constructed by the invention is good in stability, and can be used for further exploring the efficacy evaluation of uric acid lowering drugs and the mechanism of organ change caused by gout.

The invention belongs to the technical field of biological medicines, and discloses application of a deep-sea butyrolactone compound in preparation of a product for preventing and / or treating hyperuricemia and / or uric acid nephropathy. The butyrolactone compound disclosed by the invention is specifically 5-acetyl-3-hydroxy-4-(4-hydroxyphenyl)-5-[4-methyl-3-(3-methylbutyl-2-ene-1-yl) benzyl] furan-2 (5H)-ketone, and the structural formula of the butyrolactone compound is shown in the description. It is proved for the first time that the butyrolactone compound has the capacity of remarkably improving hyperuricemia and uric acid nephropathy, and the blood uric acid level, the serum creatinine level and the blood urea nitrogen level of hyperuricemia mice induced by oteracil potassium and hypoxanthine and uricase knockout mice are remarkably improved; the compound can be applied to preparation of products for preventing and / or treating the hyperuricemia and / or the uric acid nephropathy, a new product is provided for prevention and treatment of the hyperuricemia and the uric acid nephropathy, and therefore the compound has a wide application prospect.

This invention provides a method for constructing a rat model of hyperuricemia, belonging to the field of animal model construction technology. SPF-grade male rats were selected and, after adaptive feeding, were administered inosine (5-15 mg / kg), potassium oxonate (150-160 mg / kg), and hypoxanthine (100-200 mg / kg). Inosine and potassium oxonate were administered intraperitoneally, while hypoxanthine was administered subcutaneously. Experimental results showed that serum uric acid levels significantly increased one hour after modeling, and the hyperuricemic state could be maintained for up to 24 hours, significantly better than traditional models. Simultaneously, serum urea nitrogen and creatinine levels did not show significant increases, indicating that the model did not cause serious kidney damage. The hyperuricemia model constructed by this invention has a rapid onset of action, a long duration of hyperuricemia, and minimal kidney damage, making it suitable for the screening and evaluation of anti-hyperuricemia drugs.

The invention belongs to the technical field of animal models of human diseases, and particularly relates to a modeling method of a damp-heat type gout disease animal model. According to the damp-heat type gout disease animal model, the damp-heat type gout disease animal model adopts three methods of high-fat feeding, ethanol feeding and artificial climate box to jointly induce an animal to generate damp-heat syndrome, adopts three methods of hypoxanthine intragastric administration, oteracil potassium intraperitoneal injection and sodium urate joint injection to jointly induce the animal to generate gout disease, and combines the diseases and the syndromes; the obtained animal model can better simulate the human damp-heat gout disease, so that the animal model can be used for pharmacodynamic research or pathological mechanism research and the like.

This invention discloses two strains of *Lactobacillus reuteri* that are highly efficient at degrading nucleosides and their applications. *Lactobacillus reuteri* ( Limosilactobacillus reuteri The *Lactobacillus reuteri* strains W6-12 and W6-5, with accession numbers GDMCC No. 67938 and GDMCC No. 67937, respectively, exhibit efficient in vitro degradation of adenosine, guanosine, and inosine. In vivo, they significantly reduce serum uric acid levels in HUA broiler chickens induced by high calcium and high protein intake. Their fermented milk significantly reduces serum uric acid levels in SD rats with hyperuricemia induced by potassium hypoxanthine and hypoxanthine. This invention has been confirmed at multiple levels, including genetic and animal studies, to pose no potential harm to humans, demonstrating its safety and high efficiency.